Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 14/20 | 0.74 |
| ▸ | EGFR | P00533 | 9/20 | 0.74 |
| ▸ | RET | P07949 | 2/20 | 0.73 |
| ▸ | GAK | O14976 | 1/20 | 0.73 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.73 |
| ▸ | STK10 | O94804 | 1/20 | 0.73 |
| ▸ | FLT3 | P36888 | 1/20 | 0.73 |
| ▸ | JAK3 | P52333 | 1/20 | 0.73 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.73 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.73 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.73 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.73 |
| ▸ | RPS6KA6 | Q9UK32 | 1/20 | 0.73 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.73 |
| ▸ | LCK | P06239 | 3/20 | 0.71 |
| ▸ | AURKA | O14965 | 1/20 | 0.70 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.70 |
| ▸ | FLT1 | P17948 | 1/20 | 0.69 |
| ▸ | CLK1 | P49759 | 1/20 | 0.68 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5477767 | 0.99 | EGFR (0.73) | KDREGFRRETGAKRIPK2 | |
| SCHEMBL6688859 | 0.94 | KDR (0.67) | KDREGFRRETGAKRIPK2 | |
| SCHEMBL6689820 | 0.93 | AURKB (0.73) | KDREGFRRETGAKRIPK2 | |
| SCHEMBL6689899 | 0.92 | AURKB (0.69) | KDREGFRRETGAKRIPK2 | |
| SCHEMBL6691540 | 0.90 | KDR (0.66) | KDREGFRIRAK4AURKB | |
| SCHEMBL6686765 | 0.89 | EGFR (0.79) | KDREGFRRETGAKRIPK2 | |
| SCHEMBL5569469 | 0.89 | KDR (0.72) | KDREGFRRETGAKRIPK2 | |
| SCHEMBL5485308 | 0.87 | EGFR (0.77) | KDREGFRRETGAKLCK | |
| SCHEMBL18158156 | 0.87 | AURKB (0.80) | KDREGFRRETGAKRIPK2 | |
| Hydrochloric Acid SCHEMBL8809205 | 0.86 | AURKB (0.78) | KDREGFRRETGAKRIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513267-B2 | 4-anilinoquinazoline derivatives with adenosine-kinase inhibitor properties | UNIVERSIDADE ESTADUAL DE CAMPINAS-UNICAMP (BR) | 2013-08-20 | — | — | US | disclosed |
| EP-1737832-B1 | 4-ANILINOQUINAZOLINE DERIVATIVES WITH ADENOSINE-KINASE INHIBITORY PROPERTIES | UNICAMP (BR) | 2011-12-14 | — | — | EP | disclosed |
| US-20070060600-A1 | 4-Anilinequinazolines with adenosine-kiase inhibitor properties | UNIVERSIDADE ESTADUAL DE CAMPINAS-UNICAMP (BR) | 2007-03-15 | — | — | US | disclosed |
| WO-2004069145-A2 | ANTICANCER COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DR. REDDY'S LABORATORIES LTD. (IN) | 2004-08-19 | — | — | WO | disclosed |
| WO-2004013091-A2 | 4-ANILIDO SUBSTITUTED QUINAZOLINES AND USE THEREOF AS INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR KINASES | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060600-A1 | 4-Anilinequinazolines with adenosine-kiase inhibitor properties | ADK, AK1, ADORA3 | KDR 1289/4885EGFR 3142/4885RET 3198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.